Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02023463 · ClinicalTrials.gov registry record · Phase 1
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
A Phase 1 study of Recurrent Prostate Cancer and Stage IV Prostate Cancer, sponsored by Thomas Jefferson University.
- Active
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02023463 is a Phase 1 study of Recurrent Prostate Cancer and Stage IV Prostate Cancer that is active but no longer recruiting, run by Thomas Jefferson University. The registered enrollment target is 25 participants, below the 138-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02023463, a Phase 1 study of Recurrent Prostate Cancer and Stage IV Prostate Cancer, is active but no longer recruiting, sponsored by Thomas Jefferson University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial studies the side effects and best way to give enzalutamide, radiation therapy, and hormone therapy in treating patients with intermediate or high-risk prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as enzalutamide, may lessen the amount of androgens made by the body. Radiation therapy uses high energy x rays to kill tumor cells. Giving enzalutamide, radiation therapy, and hormone therapy may be an effective treatment for prostate cancer.
Conditions Studied
Interventions
- DRUG Leuprolide acetate
- DRUG Enzalutamide
- RADIATION Radiation therapy
- DRUG Goserelin acetate
Study Locations (1)
Pennsylvania
- Thomas Jefferson University - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-04-02 |
| Est. Completion | 2040-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02023463
The ClinicalTrials.gov registry entry for NCT02023463 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 138-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Recurrent Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Leuprolide acetate is the first listed.
NCT02023463 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02023463 about?
NCT02023463 is a clinical study titled "Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer". This phase I trial studies the side effects and best way to give enzalutamide, radiation therapy, and hormone therapy in treating patients with intermediate or high-risk prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as enzalutamide, may lessen th...
What is the current status of trial NCT02023463?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2014-04-02. Estimated completion is 2040-01-01.
What conditions does trial NCT02023463 study?
This clinical trial studies the following conditions: Recurrent Prostate Cancer, Stage IV Prostate Cancer, Adenocarcinoma of the Prostate, Stage III Prostate Cancer, Stage IIB Prostate Cancer.
What interventions are being tested in trial NCT02023463?
The interventions under investigation include: Leuprolide acetate (DRUG), Enzalutamide (DRUG), Radiation therapy (RADIATION), Goserelin acetate (DRUG).
Who is sponsoring clinical trial NCT02023463?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02023463 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
RECRUITING · Phase 1
-
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
RECRUITING · Phase 1
-
Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
ACTIVE NOT RECRUITING · Phase 1
-
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.